![GT Biopharma Inc](/common/images/company/N_GTBP.png)
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.185 | -6.64272890485 | 2.785 | 2.84 | 2.53 | 9454 | 2.67289913 | CS |
4 | -0.12 | -4.41176470588 | 2.72 | 2.96 | 2.53 | 13063 | 2.78182283 | CS |
12 | -0.72 | -21.686746988 | 3.32 | 10.6599 | 2.53 | 1527325 | 7.16153808 | CS |
26 | -3.673 | -58.5525267017 | 6.273 | 10.6599 | 2.53 | 710594 | 7.11883284 | CS |
52 | -5.611 | -68.335160151 | 8.211 | 10.6599 | 2.53 | 425966 | 7.19782937 | CS |
156 | -300.7 | -99.142762941 | 303.3 | 355.2 | 2.53 | 292747 | 46.95086697 | CS |
260 | -162.4 | -98.4242424242 | 165 | 591.993 | 2.53 | 326828 | 109.35046302 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.